Publications
Publications
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (518)
- November 2006
- Case
Competitive Headaches (A): The Analgesic Wars
By: Dennis A. Yao
Addresses the problem of competing with a me-too consumer product. Focuses on Bristol-Meyers' 1975 strategy for introducing a competitor to Tylenol in the analgesic market. View Details
- November 2006 (Revised July 2008)
- Case
Eli Lilly: Developing Cymbalta
By: Elie Ofek and Ron Laufer
Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta... View Details
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
- November 2006
- Case
Selling Biovail Short
By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia
Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details
- November 2006 (Revised May 2007)
- Supplement
Corporate Venture Capital at Eli Lilly
- 2006
- Book
Science Business: The Promise, the Reality, and the Future of Biotech
By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
- October 2006
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)
By: Lynn S. Paine
- September 2006
- Teaching Note
Corporate Venture Capital at Eli Lilly (TN)
By: Richard G. Hamermesh and Erin Seefeld
- September 2006 (Revised March 2010)
- Case
Teva Pharmaceutical Industries, Ltd
By: Tarun Khanna, Krishna G. Palepu and Claudine Deborah Madras
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's first and largest multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
- June 2006 (Revised January 2012)
- Supplement
Teena Lerner: Dividing the Pie at Rx Capital (B)
By: Boris Groysberg and Robin Abrahams
- June 2006
- Teaching Note
Vertex Pharmaceuticals: R&D Portfolio Management (A), (B), and (C) (TN)
By: Francesca Gino and Gary P. Pisano
- May 2006
- Teaching Note
WuXi PharmaTech (TN)
By: Richard G. Hamermesh and Erin Seefeld
Keywords: Pharmaceutical Industry
- April 2006
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (B)
By: Francesca Gino and Gary P. Pisano
Keywords: Pharmaceutical Industry
- April 2006
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (C)
By: Francesca Gino and Gary P. Pisano
Keywords: Pharmaceutical Industry
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- March 2006 (Revised February 2009)
- Teaching Note
Molecular Insight Pharmaceuticals, Inc. (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-067). View Details
Keywords: Pharmaceutical Industry
- February 2006 (Revised February 2009)
- Case
AIDS in Brazil
By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details
- February 2006 (Revised July 2007)
- Case
Corporate Venture Capital at Eli Lilly
By: Richard G. Hamermesh, Ron Laufer and David Lane
Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details
- January 2006 (Revised May 2007)
- Case
Endo Pharmaceuticals (A): From LBO to...?
By: Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details